LAGUNA HILLS, Calif., Aug. 6, 2015 /PRNewswire/ -- NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, is pleased to announce that it has engaged Ms. Kay Metis as Vice President of Strategic Alliances. Ms. Metis has over twenty years of experience developing business strategies, building professional networks, fundraising, and investor relations for both for-profit and non-profit healthcare companies.
"Throughout my career I've advanced organizations whose missions were to create innovative health care strategies and products focused on improving patient care, increasing safety, and lowering healthcare costs," explains Ms. Metis. "I am excited to join NanoSmart as they work to bring their platform technologies to pediatric cancer patients."
Ms. Metis served as Senior Director of Healthcare Strategy at West Health Institute in La Jolla, CA, founded by the Gary & Mary West Foundation – a non-profit organization with the mission of pioneering new and smarter technologies, policies, and practices to make high-quality healthcare more accessible at a lower cost to all Americans. She also served as a director of Strategy and Development for the University of Chicago Medical Center and held director positions at the Eisenhower Medical Center and Annenberg Center for Health Sciences (Rancho Mirage, CA).
"Forming strategic alliances and collaborative relationships with a wide range of entities – from patient advocacy groups to other companies with aligned business goals – is a critical part of our company's growth and sustainability," states Dr. James Smith, President of NanoSmart. "With her extraordinary background, Kay is ideally suited to fill this critical role for NanoSmart and we are very pleased to welcome her to our growing team as we work towards the commercialization of our initial products."
About NanoSmart Pharmaceuticals, Inc.
NanoSmart Pharmaceuticals, Inc. is a privately-held company engaged in developing novel methods to treat cancer and other diseases. The company is focused on using its patented tumor targeting antibodies to develop a variety of biopharmaceuticals to treat many different types of cancer. This press release may contain forward-looking statements that involve risks and uncertainties associated with product development and other business operations. NanoSmart's drug compounds are not approved by the FDA or other comparable regulatory agencies. There can be no assurance that these forward-looking statements will prove to be accurate, and they should not be regarded as a representation that the objectives and plans will be achieved.
Dan Thiel, Investor Relations
(310) 951-3282; email@example.com
SOURCE NanoSmart Pharmaceuticals, Inc.